| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Cell Growth & Differentiation, Vol 5, Issue 4 373-384, Copyright © 1994 by American Association of Cancer Research
ARTICLES |
J Dimitroulakos, J Squire, G Pawlin and H Yeger
Department of Pathology, Hospital for Sick Children, Toronto, Canada.
Human NB cell lines express features of one or more of three recognizable phenotypes that include N-type (neuroblastic), S-type (Schwannian), and I-type (intermediate phenotype) cells. The I-type cell, which shares properties of both N- and S-type cells, is thought to represent the progenitor cell from which the other two cell types are derived. The MYCN amplified NB cell line NUB-7, established in our laboratory, is now shown to be composed principally of I-type cells. The observed phenotype was stable in culture and was representative of the original surgically resected tumor. The I-type cell designation was established based on morphological characteristics, the coexpression of various N-type (neurofilaments, peripherin, GAP-43, NCAM, MYCN) and S-type cell (vimentin, laminin, fibronectin) markers, and the relatively high level of expression of these markers in comparison to five predominantly N-type, one S-type, and one N/S mixed NB cell lines. Dibutyryl cyclic AMP and retinoic acid induced enhanced expression of N- and S-type phenotypes, respectively, in NUB-7 as supported by specific morphological changes, reduced growth, and changes in the levels of expression of both N- and S-type markers. Our studies with the NUB-7 cell line have now provided convincing evidence for the existence of a bipotential progenitor of N- and S-type cells in NB. As well, the NUB-7 cell line may also represent the tumor counterpart of a sympathetic ganglion progenitor cell.
This article has been cited by other articles:
![]() |
L. Cerchia, A. D'Alessio, G. Amabile, F. Duconge, C. Pestourie, B. Tavitian, D. Libri, and V. de Franciscis An Autocrine Loop Involving Ret and Glial Cell-Derived Neurotrophic Factor Mediates Retinoic Acid-Induced Neuroblastoma Cell Differentiation Mol. Cancer Res., July 1, 2006; 4(7): 481 - 488. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Nowak, K. Kerl, D. Fehr, C. Kramps, C. Gessner, K. Killmer, B. Samans, B. Berwanger, H. Christiansen, and W. Lutz BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res., January 1, 2006; 34(6): 1745 - 1754. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Das, H. Yeger, R. Tsuchida, R. Torkin, M. F.W. Gee, P. S. Thorner, M. Shibuya, D. Malkin, and S. Baruchel A Hypoxia-Driven Vascular Endothelial Growth Factor/Flt1 Autocrine Loop Interacts with Hypoxia-Inducible Factor-1{alpha} through Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase 1/2 Pathway in Neuroblastoma Cancer Res., August 15, 2005; 65(16): 7267 - 7275. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Torkin, J.-F. Lavoie, D. R. Kaplan, and H. Yeger Induction of caspase-dependent, p53-mediated apoptosis by apigenin in human neuroblastoma Mol. Cancer Ther., January 1, 2005; 4(1): 1 - 11. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Dimitroulakos, D. Nohynek, K. L. Backway, D. W. Hedley, H. Yeger, M. H. Freedman, M. D. Minden, and L. Z. Penn Increased Sensitivity of Acute Myeloid Leukemias to Lovastatin-Induced Apoptosis: A Potential Therapeutic Approach Blood, February 15, 1999; 93(4): 1308 - 1318. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |